PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$31.73 USD
+0.80 (2.59%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $31.74 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
PTC Therapeutics (PTCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$38.75 | $62.00 | $25.00 | 25.28% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for PTC Therapeutics comes to $38.75. The forecasts range from a low of $25.00 to a high of $62.00. The average price target represents an increase of 27.51% from the last closing price of $30.39.
Analyst Price Targets (12)
Broker Rating
PTC Therapeutics currently has an average brokerage recommendation (ABR) of 2.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.62 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, five are Strong Buy, representing 38.46% of all recommendations. A month ago, Strong Buy represented 38.46%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 4 |
Sell | 1 | 1 | 1 | 1 | 2 |
Strong Sell | 2 | 2 | 2 | 3 | 3 |
ABR | 2.62 | 2.62 | 2.62 | 2.79 | 2.84 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
6/21/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Strong Buy |
5/21/2024 | Goldman Sachs | Paul K Choi | Strong Sell | Strong Sell |
5/21/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
5/19/2024 | SVB Securities | Joseph P Schwartz | Hold | Hold |
4/25/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Hold | Hold |
3/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Hold | Hold |
3/1/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.62 |
ABR (Last week) | 2.62 |
# of Recs in ABR | 13 |
Average Target Price | $38.75 |
LT Growth Rate | 39.90% |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -1.01 |